Discovery of CP-96,345 and its characterization in disease models involving substance P
| Autor: | Stevin H. Zorn, Yoshihito Kanai, R.M. Snider, Osamu Suga, John A. Lowe, Jon Bordner, Susan E. Drozda, Stafford McLean, Jackson Elisa Rose, Megumi Tsuchiya, Atsushi Nagahisa, Jean Morrone, Dianne K. Bryce, Kelly P. Longo |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
medicine.medical_specialty
Physiology Clinical Biochemistry Pain Inflammation Substance P Pharmacology Binding Competitive Biochemistry Cellular and Molecular Neuroscience chemistry.chemical_compound Endocrinology Internal medicine medicine Animals Receptor Neurotransmitter Analgesics Chemistry Biphenyl Compounds Antagonist Chronic pain Receptors Neurokinin-2 medicine.disease Asthma Disease Models Animal Nociception NK1 receptor antagonist medicine.symptom |
| Zdroj: | Regulatory Peptides. 46:20-23 |
| ISSN: | 0167-0115 |
| DOI: | 10.1016/0167-0115(93)90006-t |
| Popis: | Studies with CP-96,345, a potent, selective, orally active, nonpeptide NK1 receptor antagonist, have provided considerable insight into SP pharmacology. Rather than being a primary neurotransmitter, SP prolongs the nociception produced by other neurotransmitters. By controlling endothelial permeability, SP plays a major role in inflammation and inflammatory aspects of asthma, possibly by regulating the access of neutrophils to an inflammatory site. These results indicate potential therapeutic applications for SP antagonists in the treatment of chronic pain, inflammation, and inflammatory aspects of asthma, and signal a new era in the clinical management of these important diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|